INmune Bio raises $4.8M in gross proceeds through registered direct offering

INmune Bio has entered into definitive agreements for the sale and purchase of 571,592 shares of its common stock with above market warrant exercise price that include an acceleration clause upon positive top-line data in the Company’s Phase 2 Alzhzimer’s Disease program. The warrants give the investor the right to purchase 571,592 additional shares of its common stock in a registered direct offering. The offering was priced at the market based on the Friday, April 19th Nasdaq consolidated closing bid price of $8.32 per share. The exercise price of the warrants is $9.152, which represents a 10% premium to the price at which the common shares were offered. The warrants terminate on the earlier of the two year anniversary of the initial exercise date of the warrant or thirty trading days following the reporting of top line data in the Phase 2 Alzheimer’s program of XPro1595. The gross proceeds of this offering are approximately $4.8 million before deducting placement agent fees and expenses. The closing of the offering is expected to occur on or about April 24, 2024, subject to the satisfaction of customary closing conditions. Members of management and the Company’s board of directors and certain key employees participated in the offering and will pay a combined offering price for the common stock and warrants of $8.445 per share and warrant, and in the case of officers and directors that participated in the offering, if the warrant termination date is on a blackout date then the officers and directors will have an additional 60 days from the termination of the blackout date to exercise the warrant. The Company intends to use the net proceeds for completing the ongoing Phase 2 trial in patients with Early Alzheimer’s Disease using XPro and the metastatic castration-resistant prostate cancer Phase 1 trial using the INKmune technology. LifeSci Capital is acting as sole placement agent for this offering.